Unlocking significant potential
NeRRe’s ambition is to unlock the significant potential of its unique neurokinin-1 receptor antagonist (NK-1RA) pipeline, and in particular to progress orvepitant to full Phase 3 readiness.
NeRRe’s ambition is to unlock the significant potential of its unique neurokinin-1 receptor antagonist (NK-1RA) pipeline, and in particular to progress orvepitant to full Phase 3 readiness in the lead indication of chronic refractory cough (CRC) by 2019. The depth of the pipeline also allows for other neuronal hypersensitivity conditions and additional cough indications to be explored.
The company’s two earlier stage selective NK-1RA development compounds are NT-949 which is Phase 1 ready and NT-432 which is at the candidate selection stage ready to enter pre-clinical development.
The selective NK-1Ras in NeRRe’s portfolio have the potential to treat a range of chronic conditions caused by neuronal hypersensitivity associated with NK-1R system dysfunction, such as chronic refractory cough (CRC). There is a good biological rationale, including pre-clinical models of the disease, underlying the importance of the NK-1 receptor and its primary endogenous ligand, Substance P (SP), as mediators of chronic refractory cough. The potential for orvepitant to return to normal functioning the hypersensitive neuronal networks is clear.
Orvepitant has been administered to approximately 900 individuals to date and has demonstrated a clear benefit in reducing CRC in an open label Phase 2a study (VOLCANO-1). This proof of concept pilot trial was the basis for progressing this NK-1RA into the ongoing Phase 2b study (VOLCANO-2). In this fully powered, dose-ranging, randomised, placebo-controlled trial, orvepitant is being taken by patients orally once-daily for 12 weeks and the primary efficacy endpoint (awake cough frequency) is being measured using an objective ambulatory cough monitor.